Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
OwnerWayne P. Francoinventor
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
Claims15
A method for the systematic multi-tiered treatment of heart disease by delivery of therapeutic growth factor proteins comprising the steps of:
- a.) selecting a patient displaying symptoms of heart disease;
- b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation by oral inhalation;
- c.) monitoring levels of CPK-MB in the patient;
- d.) determining whether administration of the growth factor protein formulation was effective in treating the symptoms of heart disease in the patient;
- e.) administering one or more additional doses of a second growth factor protein formulation by a method of delivery more invasive than delivery by oral inhalation;
- and
- f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of heart disease in the patient, or until there is a contraindication to continued treatment.
A method for the administration of therapeutic amounts of a growth factor protein formulation in the treatment of heart disease comprising the step of delivering the protein formulation by inhalation therapy.
A method for monitoring clinical effectiveness of administration of a growth factor protein formulation in the treatment of heart disease, the method comprising the steps of:
- a.) obtaining a sample of a biological fluid from a patient displaying symptoms of heart disease;
- b.) performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
- c.) administering a therapeutic amount of a growth factor protein formulation to the patient;
- and
- d.) repeating steps b.) and c.) until the assayed amount of CPK-MB in the biological fluid has decreased by an amount sufficient to indicate the clinical effectiveness of the administration of the growth factor protein formulation.
Dependencies are inferred from the claim text.